TNFSF11 and Miyoshi myopathy: Bortezomib inhibits osteoclast differentiation induced by the RANKL, stimulates osteoblast differentiation and inhibits autocrine/paracrine signaling in MSCs and in ECM. PIs also reduce MM adhesion to BMSCs[15,16,17,24,33-35]